- Home
- Equipment
- north america
- car t cells
Show results for
Refine by
Car T Cells Equipment Supplied In North America
29 equipment items found
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
CAR T-cell therapy has recently emerged as a revolutionary and potentially curative therapy for patients with certain hematologic malignancies, including refractory cancers. In 2017, two CAR T-cell therapies were approved by the FDA for the treatment of relapsed / refractory ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-02 is an investigational CAR T therapy that engineers an all-in-one vector approach in patient’s T cells to express both (i) the NKG2D chimeric antigen receptor, a receptor expressed on natural killer (NK) cells that binds to eight stress-induced ligands (NKG2DL) expressed on tumor ...
by:Caribou Biosciences, Inc. based inBerkeley, CALIFORNIA (USA)
CAR-T cell therapies are a class of treatments in which T cells are modified to express chimeric antigen receptors (CARs). CARs are engineered molecules that, when present on the surface of a T cell, enable a T ...
Manufactured by:Trailhead Biosystems Inc. based inBeachwood, OHIO (USA)
We are developing cell culture media for T-cell subtype control to improve clinical potency in the individual patient and reduction of variability in outcomes between patients. CAR T-cell therapy involves the treatment of cancer by modifying a patient’s ...
by:Sorrento Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
Sorrento utilizes a proprietary knock-out knock-in (KOKI) technology to modify normal healthy donor derived T cells to genetically engineer them to express the dimeric antigen receptor into T-cell receptor (TCR) alpha chain constant region (TRAC). In this manner, TRAC is knocked out and antigen is knocked into its locus. ...
Manufactured by:Sartorius CellGenix GmbH based inFreiburg, GERMANY
CellGenix TCM is optimized for serum-free expansion and cultivation of T cells. It has been optimized and verified with CAR T cell protocols. In addition, it supports expansion of other cell types such as Treg and iNKT cells. We offer the cytokines and growth-factors needed for ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
In addition to CD38 targeting in multiple myeloma, targeting of other tumor-associated cell-surface proteins has been clinically investigated. Of these antigens, the TNF-superfamily member B-cell Maturation Antigen (BCMA) is among the most researched. Several clinical trials in multiple myeloma have shown promising initial results targeting BCMA with ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
We believe VCAR33 could be a potent anticancer therapy that, when combined with VOR33, could help obviate severe on-target myeloablative toxicities and unlock the efficacy potential of VCAR33. In addition, in this setting, VCAR33 T cells could be sourced from the same cell source as VOR33 (allogeneic cells), which may provide ...
Manufactured by:Celyad Oncology based inMont-Saint-Guibert, BELGIUM
CYAD-203 is a preclinical, non-gene edited allogeneic CAR T candidate and our first armored CAR T candidate engineered to co-express the cytokine interleukin-18 (IL-18) with the NKG2D CAR receptor. IL-18 is a proinflammatory cytokine that directly potentiates the anti-cancer activity of CAR ...
by:Caribou Biosciences, Inc. based inBerkeley, CALIFORNIA (USA)
Natural killer (NK) cells, as their name implies, play an important role in ridding the body of cancer and viruses. NK cells are emerging as an increasingly important cell type for therapeutic development. Solid tumors are particularly challenging to treat and CAR-T cells have largely ...
Manufactured by:ProImmune Ltd. based inOxford, UNITED KINGDOM
Best in class MHC Class II Monomers: ProM2® Class II MHC Monomers are pre-biotinylated and can be readily adapted either to detect and separate single-antigen specific T cells or implement specialist solid or solution phase immunoassays for measuring interactions of predefined MHC Class II-peptide complexes with ligands such as monoclonal antibodies, ...
Manufactured by:Fate Therapeutics, Inc. based inSan Diego, CALIFORNIA (USA)
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers and clinical investigators continue to focus on the development of autologous or allogeneic CAR ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1.ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity ...
Manufactured by:Access Biologicals LLC based inVista, CALIFORNIA (USA)
Human AB Serum lacks antibodies against the A and B blood type antigens, which prevents reaction with cultured cells and is recommended for use in biomedical applications. Human AB serum is regularly used for tissue engineering, transplantation and expansion of T-cells, cell therapy applications and cell line ...
Manufactured by:GeminiBio based inWest Sacramento, CALIFORNIA (USA)
GemCell Plus Xeno-Free Human Serum AB enables advanced therapy researchers and developers to streamline their workflow, allowing them to bring their end products to market quickly by providing human serum that is scalable, free of bovine components, uses therapeutic-grade human thrombin, and is rigorously ...
Manufactured by:ProImmune Ltd. based inOxford, UNITED KINGDOM
ProM1™ MHC Class I Monomers, biotin labeled enabling specialist assays for defined MHC Class I peptide target ...
by:Vor Biopharma based inCambridge, MASSACHUSETTS (USA)
Licensed from the National Institutes of Health, VCAR33 is a CD33-directed chimeric antigen receptor T cell (CAR-T) therapy. A T cell therapy using the same CAR construct as VCAR33 is being studied in a multi-site Phase 1/2 clinical trial as an autologous monotherapy ...
Manufactured by:IN8Bio Inc. based inNew York, NEW YORK (USA)
INB-300, our DeltEx DRI CAR-T, is a preclinical product candidate combining our expertise in gamma-delta T cells, our DRI technology and a novel CAR-directed against the Cholotoxin peptide. Chlorotoxin binds to GBM tumor cells and has been previously utilized as a tumor paint in this setting. ...
Manufactured by:SEQENS Group based inÉcully, FRANCE
Our Drug Delivery Solutions Business Unit coordinates our Custom Lipids activity. Seqens strongly believes in the potential of new cutting-edge technologies. In the pharmaceutical industry, lipids and polymers are core excipients in the development of drug delivery systems. Lipids and polymers can be used in most dosage forms as support vehicles, solubilizers, permeation enhancers, stabilizers, ...
Manufactured by:Celularity Inc. based inFlorham Park, NEW JERSEY (USA)
Chimeric Antigen Receptor T cells (CAR-T) are genetically engineered T cells that are modified to express an artificial T cell receptor on their surface that binds and targets cancer proteins in an HLA-independent ...